Korea’s health authorities have approved Nexletol (bempedoic acid), the first ATP-citrate lyase (ACL) inhibitor for dyslipidemia, offering a new treatment option for patients who cannot adequately control LDL cholesterol with existing therapies. Daii... [2839 chars]